There are a number of ways for investors to gain exposure to the artificial intelligence (AI) boom on the ASX.
Popular options include Megaport Ltd (ASX: MP1) and NextDC Ltd (ASX: NXT), which provide the infrastructure behind the megatrend.
Another ASX AI stock that could be worth a look is in this article. Let's see why Bell Potter is recommending it to clients.
Image source: Getty Images
Which ASX AI stock?
The ASX stock that Bell Potter is positive on is Artrya Ltd (ASX: AYA).
It is a Perth-based medical technology company using AI powered image-analysis software to improve the detection and management of coronary artery disease (CAD).
Bell Potter notes that CAD is driven by soft plaque that builds up silently in the arteries and ruptures without warning, causing a fatal heart attack.
It points out that traditional cardiac diagnostics often fail to detect this hidden risk, and in over 50% of the population, the first sign of the disease is sudden death.
The condition affects around 126 million people globally, which demonstrates the size of the opportunity for the company and its technology.
The ASX AI stock's cloud-based software, Salix, uses proprietary AI algorithms to interpret data from Coronary Computed Tomography Angiography (CCTA) scans, to deliver results in a single point-of-care solution.
Big potential returns
This morning, following a review of its FY 2026 results, Bell Potter has retained its buy rating on the ASX AI stock with a trimmed price target of $6.00 (from $6.75).
Based on its current share price, this implies potential upside of approximately 50%.
Commenting on its buy recommendation, the broker said:
While some aspects of AYA's commercialisation are occurring at a slower than expected pace, it is well advanced. AYA has two modules out of its three approved, and all three Salix modules attract top shelf category 1 CPT reimbursement rates that enable high margin generation. AYA has three customers and six study partners it aims to convert to commercial customers in time. All of this now contrasts favourably with EIQ that investors had been comparing AYA with.
While submission for the FFRCT module has taken longer than expected, now more than ever, it is imperative that AYA take the time to produce a high-quality submission with a high degree of confidence in achieving an FDA approval. Subsequent to our earnings estimate changes, we reduce our TP by c.11% to $6.00/sh and retain our BUY rating.
